biotech / news / / The Hindu Business Line
A new and higher dose of obesity drug Wegovy has joined Novo Nordisk’s semaglutide portfolio, giving patients and doctors more options for treatment.
Novo Nordisk is launching a higher 7.2 mg dose of Wegovy across Europe and the UK soon.
KEY POINTS
- Data shows early responders to high-dose Wegovy can achieve up to 28 percent weight loss.
- Novo Nordisk plans to seek regulatory approval for the higher dose Wegovy in India.
- Step-Up trial data found most high-dose Wegovy weight loss comes from fat, preserving lean mass.
- Semaglutide, both oral and injectable, has proven cardiovascular risk reduction benefits for postmenopausal women.
COMPANIES
Summarized by Newsio from The Hindu Business Line. How we summarize →